글로벌 브랜드 제네릭 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

브랜드 제네릭 시장 분석

글로벌 브랜드 제네릭 시장은 최근 몇 년 동안 수요가 엄청나게 증가했습니다. 라이센싱, 제조 및 판매와 관련된 여러 가지 내재적 및 외재적 역학이 제약 산업을 특징짓습니다. 특허 원칙은 제약 산업에서 매우 귀중합니다. 특정 기관에 특허를 받은 약물은 해당 기관에 제약 산업에서 제품을 판매할 수 있는 법적 권리를 부여합니다. 더욱이 제약 회사는 제품에 대한 특허를 받음으로써 시장에 여러 경쟁자가 존재하여 피해를 입는 것을 피할 수 있습니다. 

브랜드 제네릭 시장 규모

글로벌 브랜드 제네릭 시장 규모는 2023년에 3,411억 3,000만 달러로 평가되었으며, 2031년까지 6,328억 1,000만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 연평균 성장률은 8.03%입니다.

보고 범위 및 시장 세분화       

Branded Generics Market Definition

Branded generics are medicines or pharmaceutical drugs that have been re-released on the market under a different brand name. These are re-released at a lesser cost, and the shape, size, colour, and flavour may differ, even though the medication remains the same. This is due to the fact that the medicine's or pharmaceutical drug's patent has expired. Drugs that can be used to treat hypertension, diabetes, back pain, thyroid, and arthritis, among other conditions, are re-released at cheaper costs in order to stay in the market and survive competition. However, it is important to highlight that, despite the alterations made in the re-release of the drug, the quality remains the same. The functions that the medicine would accomplish are not compromised in any way.

Generics Market Dynamics

Drivers

• Increasing prevalence rate of chronic diseases will drive the market's growth rate

The rising prevalence rate of chronic diseases and acute ailments will propel the growth rate of branded generics market during the forecast period. Along with this growing number of cancer cases will enhance the demand for branded generics. This will further influence the market dynamics.

• Rising number of expired patents will flourish the market's growth rate

The rising number of expired patents will flourish the growth rate of branded generics market forward.

Additionally, the rising number of government initiatives to spread awareness among people will majorly influence the branded generics market's growth rate. Other significant factors resulting in the expansion of the market are the rising number of cases of trauma and accident globally and improving healthcare infrastructure. Furthermore, the rising geriatric population and favorable reimbursement policies are the major drivers that will enhance the growth of market.

Opportunities

• Growth in R&D activities

The rise in the number of research and development activities will provide beneficial opportunities for the branded generics market growth. Along with this, expansion and modernization of healthcare infrastructure across emerging economies will enhance the market's growth rate in coming years.

Moreover, technological advancement and emerging new markets will further expand the branded generics market's growth rate in the future.

Restraints/Challenges

On the other hand, entry of new market players and changing medicine practices will obstruct the market growth. Also, strict regulatory policies and huge competition from branded drugs will pose a major challenge for branded generics market. However, emergence of unfavourable conditions due to COVID-19 outbreak and lack of awareness will act as restrain and further impede the growth rate of market during the forecast period of 2024-2031.

This branded generics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the branded generics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Branded Generics Market

The impact of COVID-19 has generated an opportunity for a large number of patients, as there is a high risk of COVID-19 having negative health impacts on people. COVID-19 has raised demand for APIs and pharmaceuticals; the most in demand are those used to treat malaria, followed by bronchodilators, antibiotics, and antivirals. Sedatives, analgesics, anaesthetics, and muscle relaxants, which are used to care for patients on ventilators, are experiencing a second wave of deficiency. Because of the chronic shortage, the demand for generic medications has surged, resulting in faster FDA approval and the removal of current import warnings.

Branded Generics Market Scope

The branded generics market is segmented on the basis of product type, therapeutic application, drug class, consumption type and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Value-Added Branded Generics
• Trade Named Generics

Therapeutic Application

• Oncology
• Cardiovascular Diseases
• Diabetes
• Neurology
• Gastrointestinal Diseases
• Dermatology Diseases
• Analgesics and Anti-Inflammatory
• Others

Drug Class

• Alkylating Agents
• Antimetabolites
• Hormones
• Anti-Hypertensive
• Lipid Lowering Drugs
• Anti-Depressants
• Anti-Psychotics
• Anti-Epileptic
• Others

Consumption Type

• Oral
• Parenteral
• Topical
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Branded Generics Market Regional Analysis

The Branded generics market is analysed and market size insights and trends are provided by country, product type, therapeutic application, drug class, consumption type and distribution channel as referenced above.

The countries covered in the Branded generics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the branded generics market because of the increasing demand and adoption of branded generics across this region. Additionally, the availability of well-developed healthcare facilities will further enhance the market's growth rate in this region. 

Asia-Pacific is expected to grow during the forecast period due to rising demand for cost-effective medical or pharmaceutical drugs in this region. Also, the growing government funding will propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The branded generics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for branded generics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the branded generics market. The data is available for historic period 2010-2020.

Branded Generics Market Share

브랜드 제네릭 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우위가 있습니다. 위에 제공된 데이터 포인트는 브랜드 제네릭 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 운영되는 브랜드 제네릭 시장 리더는 다음과 같습니다.

• 애벗(미국)
• 알러간(아일랜드)
• 머크앤코(미국)
• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• 애벗(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd.(예루살렘)
• 사노피(프랑스)
• 노바티스 AG(스위스)
• Bayer AG(독일)
• Sun Pharmaceutical Industries Ltd. (뭄바이)
• 오로빈도 파마(하이데라바드)
• 루팡(뭄바이)
• 아스트라제네카(영국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 지두스 카딜라(아메다바드)
• Dr. Reddy's Laboratories Ltd., (하이데라바드)
• Apotex Inc. (캐나다) 등이 있다.

SKU-10527